



| <b>Supplemental Table S1.</b> Median overall (OS) and progression free (PFS) survival characteristics of patients with GBMs. |                       |                |               |             |              |            |             |                  |                 |
|--|-----------------------|----------------|---------------|-------------|--------------|------------|-------------|------------------|-----------------|
|  | Entire Cohort (n=207) | VSVZ + (n=111) | VSVZ - (n=96) | SGZ+ (n=23) | SGZ- (n=184) | CC+ (n=52) | CC- (n=155) | Cortex + (n=164) | Cortex - (n=43) |
| Median OS (days)   | 405                   | 323            | 498           | 371         | 426          | 215        | 473         | 426              | 326             |
| Median PFS (days)  | 162                   | 121            | 225           | 114         | 170          | 120        | 178         | 162              | 179             |



**Supplementary Figure S1. Kaplan-Meier overall survival curves of glioblastoma patients with and without VSVZ and/or corpus callosal (CC) contact.** Censored values are indicated by tick marks.



**Supplementary Figure S2. Nomogram demonstrating relative linear contributions of the variables found to be significant in multivariate Cox analysis in predicting overall survival in the study cohort.** For interpretation and use of nomograms, please refer to Gorlia, et. al., 2008 [25, 26].

**Supplementary Table S2.** Kaplan-Meier log-rank overall and progression free survival analysis based on GBMs classified by VSVZ and cortical contact.

|               | n  | Overall Survival       |                     |         | Progression Free Survival |                     |         |
|---------------|----|------------------------|---------------------|---------|---------------------------|---------------------|---------|
|               |    | Median Survival (days) | HR [95% CI]         | p-value | Median Survival (days)    | HR [95% CI]         | p-value |
| VSVZ+/cortex+ | 81 | 346                    | 0.78<br>[0.49-1.25] | 0.27    | 120                       | 1.04<br>[0.63-1.69] | 0.89    |
| VSVZ+/cortex- | 30 | 232                    |                     |         | 150                       |                     |         |
| VSVZ-/cortex+ | 83 | 492                    | 1.52<br>[0.86-2.68] | 0.21    | 197                       | 1.30<br>[0.72-2.34] | 0.41    |
| VSVZ-/cortex- | 13 | 812                    |                     |         | 312                       |                     |         |

HR = hazard ratio of cortex+ to cortex- pairs; mo = months; CI = confidence interval

**a****b****c****d**

**Supplemental Figure S3. Examples of T1 post-contrast MRIs of glioblastomas demonstrating selective tumor contrast enhancement extending towards and contacting the VSVZ (a, b) and contrast enhancement of the ipsilateral ventricular endymal surface (b-d).**